Traders Purchase High Volume of Put Options on Merck & Co (MRK)
Merck & Co (NYSE:MRK) was the recipient of some unusual options trading on Friday. Stock investors bought 14,888 put options on the company, AnalystRatingsNetwork reports. This represents an increase of approximately 116% compared to the average volume of 6,882 put options.
A number of analysts have recently weighed in on MRK shares. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Thursday. They now have a $51.00 price target on the stock. Separately, analysts at BMO Capital Markets raised their EPS on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday, September 10th. They now have a “market perform” rating and a $50.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday, September 3rd.
Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $51.03.
Merck & Co (NYSE:MRK) traded up 0.80% during mid-day trading on Monday, hitting $48.17. 1,534,582 shares of the company’s stock traded hands. Merck & Co has a one year low of $40.02 and a one year high of $50.16. The stock’s 50-day moving average is $47.92 and its 200-day moving average is $46.68. The company has a market cap of $141.0 billion and a price-to-earnings ratio of 28.62.
Merck & Co (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.84 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the prior year, the company posted $1.05 earnings per share. The company’s quarterly revenue was down 10.6% on a year-over-year basis. Analysts expect that Merck & Co will post $3.48 EPS for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.